Adam Koppel BW.png

Adam M. Koppel, MD, PhD

Adam M. Koppel rejoined Bain Capital in 2016 as Managing Director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003 where he worked as a leader within the healthcare sector until 2014. From 2014 to 2016, Dr. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. He sits on the Board of Directors of Solid Biosciences (NASD: SLDB), Dicerna Pharmaceuticals (NASD: DRNA), Aptinyx (NASD: APTX), Trevena (NASD: TRVN), and Foghorn Therapeutics. He is a former Director of PTC Therapeutics (NASD: PTCT). Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey & Co in New Jersey where he served a variety of healthcare companies. Dr. Koppel sits on the Newton-Wellesley Hospital Board of Trustees, the Partners Healthcare Innovation Advisory Board, and the Society for Neuroscience Investment Committee. He also serves on the Board of Trustees of the Boston Museum of Science. In addition, He previously sat on the Board of Temple Beth Elohim in Wellesley MA, from 2014-2017. Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an AB and AM in History and Science.